A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Trial status:Will Be Recruiting
Trial ID:
BNT326-02
NCT ID:
NCT07111520
EudraCT ID:
N/A
EU Trial (CTIS) Number:
2024-519344-32-00
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Will Be Recruiting

Trial Details

This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with BNT327 in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSCLC).

This study will enroll adult participants with histologically or cytologically confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available).

Medical Condition
  • Lung Cancer
    • Trial Drug
  • BNT326
    • See more
  • BNT327
  • Pembrolizumab
  • SoC
    • Phase
    Phase 1/Phase 2
    Type
    Interventional
    Estimated Enrolment
    420
    Estimated Trial Date
    Sep 2025 - Jan 2029

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No

    Trial Locations

    No locations found.